Phase I and II clinical trials of the small-molecule TKIs of EGFR, erlotinib and gefitinib, in ESCC treatment are being carried out and modest activity has been observed in patients with esophageal cancers [9-11]. Here, EGFR is linked to esophageal squamous cell carcinoma.